On April 17, 2024, TORL Biotherapeutics LLC closed the transaction. The company has received a $300,000 in its second and final tranche, bringing total funding to $158,300,000 in the transaction. The transaction included participation from 52 investors pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
After market 05:02:00 pm | |||
43.7 USD | -1.15% | 44 | +0.69% |
May. 01 | HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 | MT |
May. 01 | Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.83% | 89.62B | |
+29.68% | 699B | |
+25.07% | 571B | |
-4.35% | 364B | |
+17.65% | 326B | |
+3.77% | 286B | |
+14.68% | 236B | |
+4.71% | 198B | |
-12.43% | 194B | |
-3.79% | 154B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors